☆ 4.8 Article

An immune-related gene prognostic risk index for pancreatic adenocarcinoma

FRONTIERS IN IMMUNOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Comprehensive Analysis of Immune-Related Prognosis of TK1 in Hepatocellular Carcinoma

Qun Cai et al.

Summary: Increased expression of TK1 is significantly associated with the progression and prognosis of hepatocellular carcinoma (HCC). TK1 expression is related to pathological stage, tumor stage, lymph node metastasis, and immune cell infiltration in HCC. A prognostic risk score based on TK1-related immune genes can predict the survival rate of HCC patients. TK1 may be a potential immunotherapy target for HCC, and the two immune genes related to TK1 can serve as promising prognostic biomarkers.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

A Novel Immune-Related Prognostic Signature Predicting Survival in Patients with Pancreatic Adenocarcinoma

Xiao Zhang et al.

Summary: This study screened and validated four immune-related genes as prognostic biomarkers for pancreatic adenocarcinoma (PAAD). An immune-related prognostic index and nomogram were established, showing great potential for prognosis prediction and guiding more effective immunotherapy strategies in PAAD.

JOURNAL OF ONCOLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Dilemma and Challenge of Immunotherapy for Pancreatic Cancer

Jia Wu et al.

Summary: Pancreatic cancer is a highly malignant tumor with limited application of immunotherapy due to its unique biological behavior and tumor microenvironment. The immunosuppressive microenvironment of pancreatic cancer presents challenges for immunotherapy, which requires tumor immune reprogramming to improve response.

DIGESTIVE DISEASES AND SCIENCES (2021)

Add to Collection

Article Pathology

Association Between TP53 Mutation and Prognosis in Wilms Tumor: A Meta-Analysis

Li Lizhi et al.

Summary: The meta-analysis demonstrated an association between TP53 mutations and poorer prognosis in patients with Wilms tumor.

FETAL AND PEDIATRIC PATHOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabine

Ting Li et al.

Summary: PDAC is a lethal cancer with poor survival rates due to poor treatment response. The study identified S100A16 as a potential therapeutic target for PDAC treatment, showing its correlation with poor prognosis and role in promoting cancer cell metastasis through EMT and TWIST1/STAT3 signaling pathway.

BIOCHEMICAL PHARMACOLOGY (2021)

Add to Collection

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Significance of intratumoral infiltration of B cells in cancer immunotherapy: From a single cell perspective

Sijia Gu et al.

Summary: The article summarizes the current application of immunotherapy in cancer treatment, focusing on the importance and potential clinical application prospects of tumor-infiltrated B cells in anti-tumor immunity.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)

Add to Collection

Article Cell Biology

S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways

Dan Fang et al.

Summary: The S100A16 gene, located on chromosome 1q21, is significantly upregulated in pancreatic ductal adenocarcinoma (PDAC) samples. It promotes PDAC progression through FGF19-mediated AKT and ERK1/2 signaling, indicating S100A16 as a promising therapeutic target for PDAC.

CELL BIOLOGY AND TOXICOLOGY (2021)

Add to Collection

Article Oncology

S100A16 suppresses the proliferation, migration and invasion of colorectal cancer cells in part via the JNK/p38 MAPK pathway

Shiyu Ou et al.

Summary: The study revealed that S100A16 suppressed the proliferation, migration, and invasion of CRC cells partially through the JNK/p38 MAPK signaling pathway and subsequent EMT mediation.

MOLECULAR MEDICINE REPORTS (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Individualized prognostic signature for pancreatic carcinoma validated by integrating immune-related gene pairs (IRGPs)

Yecheng Li et al.

Summary: The study explores the potential clinical application of immune-regulated genes (IRGs) in pancreatic cancer prognosis, identifying an immune-regulated gene pair (IRGP) signature that predicts overall survival. Immune genes were found to be enriched in different risk groups, with distinct cell types significantly enriched in high-risk and low-risk groups. Gene ontology analysis revealed the IRGP index (IRGPI) signature genes to be primarily involved in sensory perception of a chemical stimulus and adaptive immune response, providing insights for predicting pancreatic cancer prognosis.

BIOENGINEERED (2021)

Add to Collection

Article Immunology

Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma

Bo Chen et al.

Summary: This study identified immune-related genes associated with prognosis in pancreatic adenocarcinoma and established robust prognostic models. High-risk groups based on risk scores showed poorer overall survival and progression-free survival. Two potential immune regulatory pathways and discernable patterns of DEIRGs were observed, highlighting the importance of immune-related genes in PAAD prognosis.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection

Article Oncology

Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma

Weijia Wang et al.

Summary: This study identified significant immune response differences in PDAC and developed a prognostic immune signature consisting of 5 genes that can predict overall survival in patients. The signature may serve as a powerful prognostic tool and help optimize cancer therapy.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Engineering, Biomedical

Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles

Qianwen Yu et al.

Summary: The combination of mild hyperthermia and immune checkpoint blockade treatment effectively suppressed tumor growth and metastasis; size-adjustable nanoparticles have great potential in improving cancer treatment outcomes.

ACTA BIOMATERIALIA (2021)

Add to Collection

Article Immunology

Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report

Yanghui Ye et al.

Summary: This case report highlights the effectiveness of a combination therapy of chemotherapy and immunotherapy in treating metastatic pancreatic cancer, especially in patients with SMAD4 and TSC2 mutations. The positive outcome suggests the potential of this combination therapy in large-scale clinical research to improve survival outcomes in pancreatic cancer patients.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Cell Biology

TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer

Ziwen Zhang et al.

Summary: The TP53 mutation is significantly associated with a shorter overall survival in patients with breast cancer, and is an independent predictive factor for overall survival. The TP53-mutant group exhibits higher tumor mutation burden, microsatellite instability, and tumor immune dysfunction and exclusion values for immunotherapy. In addition, TP53 mutation is related to increased ImmuneScore and StromalScore, and promotes the infiltration of Tregs, T helper cells, and M0-type macrophages in the tumor microenvironment.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Article Cell Biology

Expressional and Prognostic Value of S100A16 in Pancreatic Cancer Via Integrated Bioinformatics Analyses

Gangping Tu et al.

Summary: S100A16, highly expressed in pancreatic cancer tissues, might be associated with poor prognosis. By analyzing gene expression differences, clinical characteristics, and establishing a risk score system, the study successfully predicted the survival time of patients with PDAC.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Pancreatic Cancer: A Review

Wungki Park et al.

Summary: Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer with increasing incidence each year, resulting in a high percentage of patients being diagnosed with advanced disease. Current cytotoxic therapies for PDAC are moderately effective, emphasizing the importance of multidisciplinary management, comprehensive germline testing, and integrated supportive care for all patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Review Gastroenterology & Hepatology

Cell death in pancreatic cancer: from pathogenesis to therapy

Xin Chen et al.

Summary: Pancreatic cancer is a devastating gastrointestinal cancer with late diagnosis, limited treatment success and poor prognosis, primarily composed of pancreatic ductal adenocarcinoma (PDAC). The occurrence and progression of PDAC are influenced by various factors, and the exact impact of cell death on PDAC is not yet well described.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Cell Biology

Immune Subtypes Based on Immune-Related lncRNA: Differential Prognostic Mechanism of Pancreatic Cancer

Qiyao Zhang et al.

Summary: Pancreatic cancer is a highly malignant tumor with poor prognosis, but immunotherapy has shown promise in improving patient outcomes. This study identified immune-related lncRNA pairs, established prognostic models, and revealed significant differences in immune characteristics between subtypes. The identified lncRNA pairs may regulate immune cell anti-tumor effects through ion channel pathways, providing potential targets for immunotherapy.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer

Dujuan Cao et al.

Summary: Pancreatic cancer is a highly malignant tumor with poor prognosis, and while traditional chemotherapy and radiotherapy have improved, the 5-year survival rate remains low. New approaches like targeted therapy and immunotherapy show promise in some patient subgroups, but further research and development are needed to enhance treatment outcomes.

EXPERT REVIEWS IN MOLECULAR MEDICINE (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Construction of a novel risk model based on the random forest algorithm to distinguish pancreatic cancers with different prognoses and immune microenvironment features

Yalan Lei et al.

Summary: This study established a risk model of irlncRNAs in predicting prognosis of pancreatic cancer patients, and found that irlncRNAs were associated with immune cell infiltration and immunotherapy response. The analysis showed that irlncRNAs could be potential biomarkers for immune-related research in pancreatic cancer.

BIOENGINEERED (2021)

Add to Collection

Review Materials Science, Biomaterials

Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer

Xiaoxiao Liu et al.

Summary: Pancreatic cancer is a deadly tumor with a low survival rate due to therapeutic resistance and late-stage diagnosis. Despite limited treatment options, targeted therapy and immunotherapy offer new hope for pancreatic cancer, which has a poor prognosis.

ADVANCED BIOLOGY (2021)

Add to Collection

Review Medicine, Research & Experimental

CD40 Agonist Antibodies in Cancer Immunotherapy

Robert H. Vonderheide

ANNUAL REVIEW OF MEDICINE, VOL 71, 2020 (2020)

Add to Collection

Review Nanoscience & Nanotechnology

Nanotechnology platforms for cancer immunotherapy

Zhaogang Yang et al.

WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2020)

Add to Collection

Article Oncology

FAM83H overexpression predicts worse prognosis and correlates with less CD8+ T cells infiltration and Ras-PI3K-Akt-mTOR signaling pathway in pancreatic cancer

H. Zhuang et al.

CLINICAL & TRANSLATIONAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients

He Cheng et al.

CANCER MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I

Keisuke Yamamoto et al.

NATURE (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Role of S100 proteins in health and disease

Laura L. Gonzalez et al.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2020)

Add to Collection

Article Immunology

A signature of 18 immune-related gene pairs to predict the prognosis of pancreatic cancer patients

Fanqin Bu et al.

IMMUNITY INFLAMMATION AND DISEASE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain

Zhi-Hua Xu et al.

FASEB JOURNAL (2019)

Add to Collection

Article Gastroenterology & Hepatology

Characteristics and Outcomes of Pancreatic Cancer by Histological Subtypes

Guopei Luo et al.

PANCREAS (2019)

Add to Collection

Review Chemistry, Medicinal

Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer

Mi Jeong Kwon

ARCHIVES OF PHARMACAL RESEARCH (2019)

Add to Collection

Review Oncology

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma

M. Oliva et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Medicine, Research & Experimental

Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity

Chien-Chun Steven Pai et al.

JOURNAL OF CLINICAL INVESTIGATION (2019)

Add to Collection

Review Oncology

Harnessing the Microbiome for Pancreatic Cancer Immunotherapy

Gerardo A. Vitiello et al.

TRENDS IN CANCER (2019)

Add to Collection

Article Oncology

S100A16 is a prognostic marker for colorectal cancer

Xu Sun et al.

JOURNAL OF SURGICAL ONCOLOGY (2018)

Add to Collection

Article Immunology

The Immune Landscape of Cancer

Vesteinn Thorsson et al.

IMMUNITY (2018)

Add to Collection

Article Biotechnology & Applied Microbiology

Global identification and characterization of lncRNAs that control inflammation in malignant cholangiocytes

Bo-Wei Han et al.

BMC GENOMICS (2018)

Add to Collection

Review Oncology

The immune contexture in cancer prognosis and treatment

Wolf H. Fridman et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2017)

Add to Collection

Review Oncology

Current standards and new innovative approaches for treatment of pancreatic cancer

Thierry Conroy et al.

EUROPEAN JOURNAL OF CANCER (2016)

Add to Collection

Review Oncology

Immunotherapy for pancreatic cancer

Elias Kotteas et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)

Add to Collection

Review Multidisciplinary Sciences

Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review

Yandiswa Yolanda Yako et al.

PLOS ONE (2016)

Add to Collection

Editorial Material Oncology

PD-L1 Testing in Cancer Challenges in Companion Diagnostic Development

Aaron R. Hansen et al.

JAMA ONCOLOGY (2016)

Add to Collection

Review Oncology

Immune Therapy in GI Malignancies: A Review

Judy Wang et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Article Oncology

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Lola Rahib et al.

CANCER RESEARCH (2014)

Add to Collection

Article Oncology

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

Linda C. Sandin et al.

ONCOIMMUNOLOGY (2014)

Add to Collection

Article Immunology

Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer

Gabriela Bindea et al.

IMMUNITY (2013)

Add to Collection

Article Medicine, Research & Experimental

M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway

Chao-Ying Liu et al.

LABORATORY INVESTIGATION (2013)

Add to Collection

Article Immunology

Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection

Chao Wang et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2012)

Add to Collection

Article Oncology

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation

Dan Laheru et al.

CLINICAL CANCER RESEARCH (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.